publication date: Sep. 15, 2017

Five UC Comprehensive Cancer Centers form consortium to pool patient data for translational research

By Matthew Bin Han Ong

Five academic cancer centers within the University of California system are putting together a single consortium to integrate their electronic health records, forming a clinical trials monolith that could be used by pharmaceutical companies doing research in the Golden State.

The UC Cancer Consortium, announced Sept. 11, consists of the following NCI-designated comprehensive cancer centers:

University of California, Davis Comprehensive Cancer Center,

The Chao Family Comprehensive Cancer Center at University of California, Irvine,

The Jonsson Comprehensive Cancer Center at University of California, Los Angeles,

University of California, San Diego Moores Cancer Center, and

University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.

The UC cancer centers treat 16 percent of all cancer patients in California. The UC centers administered more than 1,600 clinical trials in the past year, accruing more than 29,000 patients. Collectively, these centers are the nation’s top recipient of research grants from NIH and of cancer research grants from NCI. They are also the largest university holder of U.S. biomedical patents.

“Our research mission and high level of skill mean that our centers often care for patients with rare cancers who cannot be treated in other hospitals that may lack the expertise or access to clinical trials using the latest experimental drugs,” John … Continue reading Five UC Comprehensive Cancer Centers form consortium to pool patient data for translational research

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.